ViewRay, Inc. (VRAY) Receives Consensus Rating of “Buy” from Analysts
ViewRay, Inc. (NASDAQ:VRAY) has been given a consensus recommendation of “Buy” by the six research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $10.60.
Several research analysts have recently commented on the stock. Mizuho reaffirmed a “buy” rating and issued a $12.00 price target on shares of ViewRay in a report on Friday, November 3rd. Northland Securities reaffirmed a “buy” rating and issued a $10.00 price target on shares of ViewRay in a report on Friday, November 17th. Finally, ValuEngine lowered shares of ViewRay from a “hold” rating to a “sell” rating in a report on Friday, September 22nd.
ViewRay (NASDAQ VRAY) opened at $9.44 on Monday. ViewRay has a fifty-two week low of $2.98 and a fifty-two week high of $10.39. The company has a debt-to-equity ratio of -1.67, a quick ratio of 1.20 and a current ratio of 1.59.
ViewRay (NASDAQ:VRAY) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). The firm had revenue of $12.20 million for the quarter, compared to analyst estimates of $18.63 million. The firm’s revenue for the quarter was up 2950.0% compared to the same quarter last year. equities research analysts expect that ViewRay will post -0.91 EPS for the current fiscal year.
A number of large investors have recently modified their holdings of VRAY. Vanguard Group Inc. lifted its position in ViewRay by 67.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,026,880 shares of the company’s stock valued at $6,644,000 after purchasing an additional 411,866 shares during the last quarter. Pura Vida Investments LLC lifted its position in ViewRay by 132.9% in the 3rd quarter. Pura Vida Investments LLC now owns 607,040 shares of the company’s stock valued at $3,497,000 after purchasing an additional 346,370 shares during the last quarter. State Street Corp lifted its position in ViewRay by 631.7% in the 2nd quarter. State Street Corp now owns 395,418 shares of the company’s stock valued at $2,555,000 after purchasing an additional 341,376 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in ViewRay by 2,447.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 286,365 shares of the company’s stock valued at $1,853,000 after purchasing an additional 275,123 shares during the last quarter. Finally, RTW Investments LP lifted its position in ViewRay by 33.5% in the 3rd quarter. RTW Investments LP now owns 1,020,462 shares of the company’s stock valued at $5,878,000 after purchasing an additional 256,127 shares during the last quarter. Hedge funds and other institutional investors own 46.99% of the company’s stock.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.